FDA approves Avastin for lung cancer

As expected, the FDA has approved Genentech's Avastin as a front line therapy for the most common kind of lung cancer. Some 162,000 Americans die every year from lung cancer. Avastin, already approved for colon cancer, will be provided to qualified patients for a discounted price of $55,000 a year, but only for approved indications. Genentech and other drug developers have been harshly criticized for demanding astronomically high retail prices on new therapies.

- read the AP report on the approval

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.